Just a few weeks after announcing that the U.S. FDA had approved its Alzheimer’s disease drug lecanemab, Eisai revealed that it would be letting go of 91 workers.
The layoffs were confirmed on a Worker Adjustment and Retraining Notification Act (WARN) alert from New Jersey. Per the notice, they will be effective on April 30th.
The cuts will come from Eisai’s Fycompa team. The anti-epileptic medication was recently sold to Catalyst Pharmaceuticals. At the time of the sale, Fycompa revenues for the 2022 fiscal year were estimated at $136 million. At the time of the acquisition, Catalyst CEO Patrick McEnany had pledged a "smooth and orderly transition of certain employees to the Catalyst team.”
